Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Backtested performance is developed with the benefit of hindsight and has inherent limitations. This information is provided for illustrative purposes only. No representations and warranties are made as to the reasonableness of the assumptions. Certain assumptions have been made for modeling purposes and are unlikely to be realized. Changes in these assumptions may have a material impact on the backtested returns presented. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested performance is not an indicator of future actual results. Meta’s Plea to Dismiss FTC’s Antitrust Suit RejectedĬitigroup Undergoes Strategic Restructuringĭisclaimer: The TipRanks Smart Score performance is based on backtested results. To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. 100% of the articles have Bullish sentiment, compared to the sector average of 58%.
News Sentiment for Abbott is Very Positive based on 29 articles over the past seven days. Shares have gained 19.2% over the past year. The average Abbott stock prediction of $145.75 implies upside potential of 9% from current levels. The analyst, however, raised the price target from $140 to $150, which implies upside potential of 12.2% from current levels.Ĭonsensus among analysts is a Strong Buy based on 11 Buys and 2 Hold. analyst Josh Jennings reiterated a Buy rating on the stock. These models provide a way to precisely identify areas that are causing problems, so physicians can better treat those abnormal heart rhythms, and preserve healthy tissue.” Analyst Ratings The Senior Vice-President of Electrophysiology at Abbott, Mike Pederson, said, “We developed the EnSite X System with EnSite OT to enhance the utility of our unique Advisor HD Grid catheter and allow doctors to quickly and accurately create real-time, stable, three-dimensional models of the heart. Further, the system has the capability to sample EGMs in 360 degrees and map a million points in the heart and provide a more precise location of treatment areas. Notably, the platform includes Abbott’s proprietary EnSite OT, which leverages the Advisor HD Grid Catheter to provide true electrograms. With a sizeable number of Americans suffering from abnormal heart rhythms each year, Abbot’s new cardiac mapping system, with its three-dimensional maps of the heart, is likely to make the life of physicians treating heart diseases simpler by identifying the areas where abnormal rhythms originate. The stock pared its loss slightly to close at $133.76 in the extended trading session. The mapping platform is aimed at assisting doctors to better treat abnormal heart rhythms.įollowing the news, shares of the company declined 1.5% on Wednesday. Medical devices and healthcare corporation Abbott Laboratories ( NYSE:ABT) recently announced that its new cardiac mapping platform, the EnSite™ X EP System with EnSite Omnipolar Technology (OT), has received clearance from the U.S. Abbott’s Cardiac Mapping System Receives FDA Approval